tetano
Editor, Senior Moderator
Vaccine. 2017 Mar 22. pii: S0264-410X(17)30322-5. doi: 10.1016/j.vaccine.2017.03.016. [Epub ahead of print]
[h=1]A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography.[/h] Tseng YF[SUP]1[/SUP], Weng TC[SUP]2[/SUP], Lai CC[SUP]2[/SUP], Chen PL[SUP]2[/SUP], Lee MS[SUP]2[/SUP], Hu AY[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Since newly emerging influenza viruses with pandemic potentials occurred in recent years, the demand for producing pandemic influenza vaccines for human use is high. For the development of a quick and efficient vaccine production, we proposed an efficient purification platform from the harvest to the purified bulk for the cell-based influenza vaccine production. This platform based on flow-through chromatography and filtration steps and the process only involves a few purification steps, including depth filtration, inactivation by formaldehyde, microfiltration, ultrafiltration, anion-exchange and ligand-core chromatography and sterile filtration. In addition, in the proposed chromatography steps, no virus capture steps were employed, and the purification results were not affected by the virus strain variation, host cells and culturing systems. The results from different virus strains which produced by Vero or MDCK cells in different culturing systems also obtained 33-46% HA recovery yields by this platform. The overall removal rates of the protein and DNA concentration in the purified bulk were over 96.1% and 99.7%, respectively. The low residual cellular DNA concentrations were obtained ranged from 30 to 130pg per human dose (15?g/dose). All influenza H5N1 purified bulks met the regulatory requirements for human vaccine use.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Cell culture; Flow-through chromatography; Influenza vaccine; Purification process
PMID: 28342667 DOI: 10.1016/j.vaccine.2017.03.016
[h=1]A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography.[/h] Tseng YF[SUP]1[/SUP], Weng TC[SUP]2[/SUP], Lai CC[SUP]2[/SUP], Chen PL[SUP]2[/SUP], Lee MS[SUP]2[/SUP], Hu AY[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Since newly emerging influenza viruses with pandemic potentials occurred in recent years, the demand for producing pandemic influenza vaccines for human use is high. For the development of a quick and efficient vaccine production, we proposed an efficient purification platform from the harvest to the purified bulk for the cell-based influenza vaccine production. This platform based on flow-through chromatography and filtration steps and the process only involves a few purification steps, including depth filtration, inactivation by formaldehyde, microfiltration, ultrafiltration, anion-exchange and ligand-core chromatography and sterile filtration. In addition, in the proposed chromatography steps, no virus capture steps were employed, and the purification results were not affected by the virus strain variation, host cells and culturing systems. The results from different virus strains which produced by Vero or MDCK cells in different culturing systems also obtained 33-46% HA recovery yields by this platform. The overall removal rates of the protein and DNA concentration in the purified bulk were over 96.1% and 99.7%, respectively. The low residual cellular DNA concentrations were obtained ranged from 30 to 130pg per human dose (15?g/dose). All influenza H5N1 purified bulks met the regulatory requirements for human vaccine use.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Cell culture; Flow-through chromatography; Influenza vaccine; Purification process
PMID: 28342667 DOI: 10.1016/j.vaccine.2017.03.016